EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)

Davor Galusic, Josip Batinic, Ivan Krecak, Barbara Dreta, Delfa Radic Kristo, Mario Pirsic, Goran Rincic, Jasminka Sincic-Petricevic, Toni Valkovic, Milan Vujcic, Marin Simunic, Karla Misura Jakobac und 13 weitere

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.100912 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Davor Galusic und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University Hospital of Split, 21000 Split, Croatia. Electronic address: davorgalusic@net.hr. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Carfilzomib-based regimens brought a significant improvement in the treatment of relapsed/refractory multiple myeloma (RRMM). Even though efficacy and safety profiles of carfilzomib are well-established in several clinical trials, there is limited real-world data with carfilzomib-based protocols. Here we present our real-world experience with carfilzomib-based regimens for treatment of patients with RRMM in Croatia. METHODS: Data on patients with RRMM starting carfilzomib-based protocols in the period between June 2019 and February 2023 was collected by retrospective chart review from 14 Croatian centres. RESULTS: A total of 119 patients with RRMM were included; median age was 66 years (range 45-83 years), 59 (49.6 %) were females, and the median number of previous lines of therapies was 2 (range 1-8). Triplet based regimen was treatment choice in 84 (70.6 %) and 35 (29.4 %) patients were treated with carfilzomib in combination with dexamethasone (Kd). Overall response rate was 61.7 %, with 20 patients (18.7 %) achieving complete response (CR). Median progression free survival (PFS) and overall survival (OS) for entire cohort were 9.4 and 13.2 months, respectively. Median PFS was 12.8 months and 4.1 months for the triplets and doublets, respectively; the corresponding median OS was 18.6 and 7.9 months, respectively. The most common adverse events were anemia and thrombocytopenia; 19 patients (16 %) experienced cardiovascular events. CONCLUSION: This is the first study to analyze clinical outcomes of RRMM patients treated with carfilzomib-based regimens in Croatia. Carfilzomib-based regimens showed substantial efficacy and acceptable toxicity in RRMM, especially in earlier treatment lines and triplet combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaNeoplasm Recurrence, LocalOligopeptidesAgedAged, 80 and overFemaleHumansMaleMiddle AgedCroatiaDexamethasoneRetrospective Studies

Stichwörter der Autor:innen

CarfilzomibLenalidomideMultiple myelomaReal-worldRelapsed/refractory

Substanzen

carfilzomibDexamethasoneOligopeptides

Autor:innen und Institutionen

  • Division of Hematology, University Hospital of Split, 21000 Split, Croatia. Electronic address: davorgalusic@net.hr.
  • Division of Hematology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Department of Internal Medicine, General Hospital of Sibenik, 22000 Sibenik, Croatia.
  • Division of Hematology, University Hospital Merkur, 10000 Zagreb, Croatia.
  • Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia.
  • Division of Hematology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia.

Zitieren

APA

Galusic, D., Batinic, J., Krecak, I., Dreta, B., Radic Kristo, D., Pirsic, M., Rincic, G., Sincic-Petricevic, J., Valkovic, T., Vujcic, M., Simunic, M., Misura Jakobac, K., Sedinic Lacko, M., Brcic, K., Perisa, V., Petricevic, F., Grohovac, D., Holik, H., Moric Peric, M., …, & Basic-Kinda, S. (2025). Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM). Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100912

Vancouver

Galusic D, Batinic J, Krecak I, Dreta B, Radic Kristo D, Pirsic M, et al. Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM). Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100912

BibTeX
@article{Galusic2025,
  author = {Galusic, Davor and Batinic, Josip and Krecak, Ivan and Dreta, Barbara and Radic Kristo, Delfa and Pirsic, Mario and Rincic, Goran and Sincic-Petricevic, Jasminka and Valkovic, Toni and Vujcic, Milan and Simunic, Marin and Misura Jakobac, Karla and Sedinic Lacko, Martina and Brcic, Klara and Perisa, Vlatka and Petricevic, Fran and Grohovac, Dragana and Holik, Hrvoje and Moric Peric, Martina and Zekanovic, Ivan and Bernes, Petra and Kuzat, Luka and Romic, Ilenia and Zupanic Krmek, Dubravka and Basic-Kinda, Sandra},
  title = {Carfilzomib in relapsed/refractory multiple myeloma patients – real world evidence – experiences of the Croatian cooperative group for hematologic diseases (KROHEM)},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.100912}
}
Kostenlos starten →